Natera ($NTRA) Insider Trading & Smart Money Activity
Natera, Inc. ($NTRA) has 13 insider trades, 6 13F position changes and 13 analyst ratings on file. In the last 12 months on the open market, no insider bought and 7 insiders sold ($52.89M), net -$52.89M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 7
- Net insider $ (12 mo)
- -$52.89M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 6
- Analyst ratings on file
- 13
NTRA insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 4 · $23.98M | 0 / 0 | 0 / 6 |
| Q3 2026 | 0 | 1 · $7.01M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 3 · $21.90M | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All NTRA insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Matthew RabinowitzEXECUTIVE CHAIRMAN | Sell (Open-market sale) 10b5-1 | 50K sh | $20.13M | -2.30% | SEC | Read | ||||
| Analyst | JP Morgan | Reiterates to Overweight | PT $460 | Read | |||||||
| Analyst | TD Cowen | Reiterates to Buy | PT $480 | Read | |||||||
| Analyst | Morgan Stanley | Reiterates to Overweight | PT $435 | Read | |||||||
| Analyst | Barclays | Reiterates to Overweight | PT $475 | -0.2% | — | ||||||
| Analyst | Citigroup | Reiterates to Buy | PT $480 | -1.2% | — | ||||||
| Insider | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Sell (Open-market sale) 10b5-1 | 3K sh | $1.24M | -4.3% | — | |||||
| Insider | Chapman Steven LeonardCEO AND PRESIDENT | Sell (Open-market sale) 10b5-1 | 1.27K sh | $526.14K | -4.3% | — | |||||
| Analyst | Guggenheim | Reiterates to Buy | PT $475 | -4.3% | — | ||||||
| Analyst | RBC Capital | Reiterates to Outperform | PT $460 | -0.5% | — | ||||||
| Insider | Sheena JonathanDirector | Sell (Open-market sale) 10b5-1 | 18.06K sh | $7.01M | +5.8% | — | |||||
| Analyst | Guggenheim | Reiterates to buy | PT $290 | +4.2% | -6.8% | Read | |||||
| Insider | Eric Rubin | Buy (Grant or award) | 75 sh | +8.4% | -1.5% | Read | |||||
| Insider | Lynch Thomas JR. | Buy (Grant or award) | 1.91K sh | +8.4% | -1.5% | Read | |||||
| Insider | Rowan Chapman | Buy (Grant or award) | 1.67K sh | +8.4% | -1.5% | Read | |||||
| Insider | Roelof Botha | Buy (Grant or award) | 1.69K sh | +8.4% | -1.5% | Read | |||||
| Insider | Roy Baynes | Buy (Grant or award) | 1.65K sh | +8.4% | -1.5% | Read | |||||
| Analyst | Bernstein | Reiterates to buy | PT $310 | +8.4% | -1.5% | Read | |||||
| Insider | Herm Rosenman | Sell (Open-market sale) 10b5-1 | 16.53K sh | $4.13M | +6.3% | +0.8% | Read | ||||
| Insider | Daniel RabinowitzSEC. AND CHIEF LEGAL OFFICER | Sell (Open-market sale) 10b5-1 | 33.60K sh | $8.46M | +6.3% | +0.8% | Read | ||||
| Analyst | BTIG | Reiterates to buy | PT $275 | +6.3% | +0.8% | Read | |||||
| Analyst | Barclays | Reiterates to buy | PT $260 | +6.3% | +0.8% | Read | |||||
| Analyst | BTIG | Reiterates to buy | PT $270 | +15.6% | +12.7% | Read | |||||
| Insider | Rowan Chapman | Sell (Open-market sale) 10b5-1 | 2.96K sh | $642.54K | +6.7% | +22.6% | Read | ||||
| Insider | Matthew RabinowitzEXECUTIVE CHAIRMAN | Sell (Open-market sale) 10b5-1 | 50K sh | $10.75M | +5.5% | +27.8% | Read | ||||
| Analyst | RBC Capital | Raises to buy | PT $275 | +7.9% | +28.7% | Read | |||||
| 13F | Rtw Investments | Reduced | -250K sh | $333.81M | +9.0% | +16.4% | Read | ||||
| 13F | Fred Alger Management | Reduced | -66.04K sh | $469.06M | +9.0% | +16.4% | — | ||||
| 13F | Farallon Capital Management | Reduced | -707K sh | $856.51M | +9.0% | +16.4% | — | ||||
| 13F | Coatue Management | Reduced | -91.49K sh | $678.79M | +9.0% | +16.4% | Read | ||||
| 13F | Lord, Abbett | Reduced | -107.54K sh | $296.82M | +3.4% | +10.2% | — | ||||
| 13F | ARK Investment Management | Reduced | -46.85K sh | $182.73M | -4.0% | +7.4% | — |
1W / 1M / 6M = how NTRA moved from the trade or filing date.
Insider trading in NTRA: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN | 2 | -$30.88M | 2.12M | Oct 15, 2026 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 1 | -$1.24M | Oct 1, 2026 | |
| Chapman Steven Leonard | CEO AND PRESIDENT | 1 | -$526.14K | Oct 1, 2026 | |
| Sheena Jonathan | Director | 1 | -$7.01M | Sep 23, 2026 | |
| Rowan Chapman | 2 | -$642.54K | Jun 26, 2026 | ||
| Eric Rubin | 1 | — | Jun 26, 2026 | ||
| Lynch Thomas JR. | 1 | — | Jun 26, 2026 | ||
| Roelof Botha | 1 | — | Jun 26, 2026 | ||
| Roy Baynes | 1 | — | Jun 26, 2026 | ||
| Herm Rosenman | 1 | -$4.13M | Jun 24, 2026 | ||
| Daniel Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 1 | -$8.46M | Jun 24, 2026 |
Institutions moving NTRA (13F)
Analyst ratings on NTRA
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| JP Morgan | Reiterates | Overweight | $360 → $460 | Read | ||||
| TD Cowen | Reiterates | Buy | $340 → $480 | Read | ||||
| Morgan Stanley | Reiterates | Overweight | $355 → $435 | Read | ||||
| Barclays | Reiterates | Overweight | $340 → $475 | -0.2% | — | |||
| Citigroup | Reiterates | Buy | $365 → $480 | -1.2% | — | |||
| Guggenheim | Reiterates | Buy | $360 → $475 | -4.3% | — | |||
| RBC Capital | Reiterates | Outperform | $350 → $460 | -0.5% | — | |||
| Guggenheim | Reiterates | buy | $290 | +4.2% | -6.8% | Read | ||
| Bernstein | Reiterates | buy | $310 | +8.4% | -1.5% | Read | ||
| BTIG | Reiterates | buy | $275 | +6.3% | +0.8% | Read |
Frequently asked questions
Are NTRA insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 7 insiders made 8 open-market sales worth $52.89M, a net -$52.89M.
What is the latest insider trade in NTRA?
Matthew Rabinowitz, EXECUTIVE CHAIRMAN filed a sell (open-market sale) of 50K sh worth $20.13M on Oct 15, 2026.
Which institutions changed their NTRA positions?
Recent 13F filers moving the stock include Rtw Investments, Fred Alger Management, Farallon Capital Management, Coatue Management and Lord, Abbett.
Other diagnostics & research stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.